Remove 2022 Remove Court Decisions Remove Statute
article thumbnail

Patent Law at the Supreme Court February 2022

Patently O

Rather, any new grant this term will very likely be pushed back to the October 2022 Term for hearing and decision. Still, there are a number of important patent cases pending before the court. 21-746 (CVSG requested February 22, 2022). 2022)(forthcoming). Lets talk them through. Qualcomm Incorporated , No.

Laws 95
article thumbnail

Reviewing the Patent Eligibility Restoration Act of 2022

Patently O

” Unfortunately, due to a series of Supreme Court decisions, patent eligibility law in the United States has become confused, constricted, and unclear in recent years. This has led to inconsistent case decisions, uncertainty in innovation and investment communities, and unpredictable business outcomes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Supreme Court Finds CMS’ Reduction of Medicare Hospital Outpatient Payment Rates for 340B Hospitals was Not Authorized by Statute

FDA Law Blog

Circuit, but today, the Supreme Court reversed again and upheld the District Court’s opinion in American Hospital Assn v. S. _ (2022). The statute sets this “average price” as ASP plus 6%. After finding that the statute was subject to statutory review, the Court turned to the merits of the case.

Statute 52
article thumbnail

4th Circuit En Banc Judgment Affirms District Court Decision in Best Price Stacking Case

FDA Law Blog

As we reported, on November 5, 2020, the District Court held that the relator could not plausibly plead the requisite scienter because Forest’s interpretation of the ambiguous statute was objectively reasonable and CMS did not warn Forest away from that interpretation through authoritative guidance. Burr , 551 U.S.

article thumbnail

The Fourth Circuit Upholds CMS’ Definition of “Line-Extension Drug” and “New Formulation”

FDA Law Blog

Under the Medicaid Drug Rebate statute, a pharmaceutical manufacturer whose drug prices increase faster than the rate of inflation must pay additional per-unit rebates to the program. The statute defines a “line extension” as a “new formulation” of an existing drug, with certain exceptions. Vanda Pharmaceuticals, Inc. 23-1457 (4th Cir.

article thumbnail

COVID – Consolidated Appropriation Act “CAA” and Bankruptcy 12-27-20

Diane Drain

It is possible that these interpretations of the new Act will change with new legislation or court decisions, so never assume what you read one day will be interpreted the same way the next day. This provision, if it becomes effective, will sunset on December 27, 2022. This provision sunsets in two years on December 27, 2022.

article thumbnail

Does the Temporary PTO Director have Arthrex Authority?

Patently O

In 2021, the Supreme Court sided with the patentee in holding that the AIA trial system violated the Appointments Clause of the U.S. The Court concluded that PTAB judges were wielding the substantial power of the U.S. Oral arguments in this round of the appeal are set for March 30, 2022. by Dennis Crouch. Arthrex, Inc.

Statute 63